When covered, GLP-1s are typically subject to utilization controls such as prior authorization, which can further limit access
In my opinion, its too early to determine what the long-term impacts of these drugs will be
Sugar-free, gluten-free, and vegan friendly
doi: 10.1113/jphysiol.2013.255364
The use of chemical modifications to increase RNA stability and reduce immunogenicity may themselves introduce new safety concerns, such as altering biodistribution or causing unanticipated toxicities
Separate-vial workflow Independent dose control for cagrilintide and semaglutide Use separate vials when you want to escalate cagrilintide and semaglutide on different schedules, hold one compound at a lower dose, or accommodate different vial concentrations